Brown & Brown, Inc. (BRO) — Q2 2026 Earnings Preview

1. Earnings Preview

Key Takeaway: Setup is modestly constructive — consensus is a manageable bar, but the single biggest swing factor is whether organic revenue (ex-contingents) shows sequential improvement from Q1's flat print, as any further deceleration would reignite debate about structural share loss from Howden defections and the pharmacy revenue headwind.

Heading into Q2 2026, the bar for BRO looks achievable but not easy. Consensus expects total revenues of ~$1.72 billion and adjusted operating EPS of ~$1.08, both representing modest year-over-year growth off a Q2 2025 base that itself carried elevated contingent commissions. The key tension is between organic revenue momentum — which was flat in Q1 (ex-contingents) and is guided to only ~0.6% for Q2 — and contingent commissions, where management reversed prior guidance and now expects full-year 2026 contingents to exceed 2025 levels, providing a meaningful offset. Management's tone on the Q1 call was notably more constructive on contingents but more cautious on core organic, introducing a new pharmacy revenue headwind (~50–100 bps to retail organic) and acknowledging Howden-related revenue losses are growing. Estimate revisions have been largely stable since the Q1 print, with the post-earnings baseline holding, suggesting the street has already digested the moving pieces. The stock has recovered from its post-Q1 lows (~$54) to ~$68, roughly flat to the Q1 earnings-day close, meaning it has not pre-priced a meaningful beat. The wildcard is CAT property rate trajectory: peers (MMC, AJG) flagged property rates down 9–12% in Q2, steeper than Q1, which could pressure BRO's Specialty Distribution organic growth and contingent commission outlook for the back half of the year.

2. KPIs & Consensus Expectations

Key Takeaway: Consensus is a low-to-moderate bar on revenues and EPS, but organic revenue growth (ex-contingents) is the bigger swing factor — any improvement from Q1's flat print would be a positive signal, while a further miss would amplify concerns about structural headwinds.

Table 1 — Current Quarter Snapshot (Q2 2026)

Source: Visible Alpha consensus and actuals data. Q2 2026 consensus as of July 26, 2026. Q1 2026 actuals reported April 27, 2026. Q2 2025 actuals as reported. YoY change for Total Revenues reflects Accession acquisition impact (closed Q4 2025). Organic revenue growth consensus of ~0.6% reflects Core commission and fees — Organic impact (%) from Visible Alpha.

Table 2 — Beat/Miss History (Last 8 Quarters, Top 2 KPIs)

Top 2 KPIs: (1) Organic Revenue Growth (%) and (2) Adjusted Diluted EPS — Operating ($)

Pattern: BRO has beaten adjusted EPS consensus in all 8 of the last 8 quarters, typically by $0.03–$0.16. Organic revenue growth, however, has missed consensus in 5 of the last 8 quarters, with misses accelerating in recent periods as the pricing environment softened and Accession integration headwinds emerged. The EPS beat pattern is durable; the organic growth miss pattern is the market's primary concern.

Source: Visible Alpha consensus and actuals data.

3. Guidance & Commentary Evolution

Key Takeaway: Management's most significant post-Q1 guidance shift was the reversal on full-year contingent commissions — from a modest decline to above 2025 levels — while core organic growth guidance remains cautious with no specific Q2 target, and the new pharmacy revenue headwind adds a fresh drag not previously in the model.

4. Guidance vs. Estimate Revision Tracker

Key Takeaway: Estimates have been broadly stable since the Q1 print, with only modest downward drift in organic growth expectations — the gap between consensus and guidance is narrow, suggesting the street has largely priced in management's cautious tone; the main risk is if Q2 organic comes in below the already-low ~0.6% bar.

Estimates have been remarkably stable since the Q1 print, with virtually no revision across any KPI (all within ±1.3%). The street appears to have fully digested management's cautious organic growth tone and the new pharmacy headwind, with consensus now tracking just below management's directional guidance on organic growth. The contingent commission consensus of ~$302M for FY 2026 sits well above management's floor of >$250M, suggesting the market is giving credit for the strong Q1 contingent beat to continue through the year.

Source: Visible Alpha consensus data. Post-Q1 baseline as of approximately May 2, 2026 (5 trading days after April 27, 2026 earnings release). Current consensus as of July 26, 2026.

5. Stock Performance

Key Takeaway: BRO has significantly underperformed both the sector ETF (IAK) and the S&P 500 since the Q1 earnings date, with the stock up only ~2.3% vs. IAK +12.2% and SPY +3.3%, driven by multiple compression on organic growth concerns rather than estimate revisions, which have been flat.

BRO vs. IAK (Insurance ETF) vs. S&P 500 — Indexed to 100 at Q1 2026 Earnings Date (April 27, 2026). Source: Stock Price Data.

BRO opened the post-Q1 period at $66.12 on April 27, 2026 and has traded to ~$67.66 as of July 25, 2026 — a gain of only ~2.3% — while the iShares U.S. Insurance ETF (IAK) gained ~12.2% and the S&P 500 gained ~3.3% over the same period. The stock sold off sharply in the first two weeks post-earnings (reaching a low of ~$54 in mid-May), as the market digested the flat organic growth print, the new pharmacy headwind, and growing Howden-related revenue losses. The recovery from those lows to the current ~$68 level has been driven by the broader insurance sector re-rating (IAK +12%) and some stabilization in sentiment, but BRO has not kept pace with peers. The stock's underperformance vs. IAK (~1,000 bps) reflects the market's view that BRO's organic growth profile is structurally weaker than peers in the current environment. At ~$68, BRO trades at approximately 15x NTM EBITDAC — a meaningful discount to its historical average and to large-cap peers (MMC, AON, AJG), consistent with the depressed sentiment described in the valuation section. The stock has recovered to roughly its Q1 earnings-day close, suggesting neither a beat nor a miss is priced in heading into Q2.

6. Peer Commentaries — Q2 2026 Read-Through

Key Takeaway: Peer commentary is a mixed read-through for BRO: MMC's Q2 2026 results confirm accelerating CAT property rate declines (a headwind for BRO's Specialty Distribution contingents), but also show that strong new business and casualty pricing can offset rate pressure — and AJG's pre-Q2 investor meeting signals mid-single-digit organic growth is achievable even in this environment, raising the bar for BRO's own organic trajectory.

The following commentary is drawn exclusively from peer events occurring after BRO's Q1 2026 earnings (April 27, 2026) and relevant to BRO's current Q2 2026 reporting period.

MMC (Marsh McLennan) — Q2 2026 Earnings Call (July 21, 2026)

Relevance: MMC is BRO's closest large-cap peer in commercial P&C brokerage and reinsurance. MMC's Q2 2026 results are the most direct read-through for BRO's Q2 environment.

• CAT Property Rates Accelerating Lower — Headwind for BRO Specialty Distribution: Global property rates fell 12% YoY in Q2 2026, accelerating from -5% in Q1. Guy Carpenter's property CAT rate online index was down 16% at midyear — the steepest YoY decline in 25 years. Florida CAT renewals saw 15–20% rate reductions. This is a direct headwind for BRO's Specialty Distribution segment, which generates contingent commissions tied to underwriting profitability. However, BRO management noted on the Q1 call that the inverse correlation between rate softness and contingent income is a feature, not a bug — softer rates tend to improve carrier underwriting results, which drives higher contingents.
• Casualty Rates Remain Firm — Positive for BRO Retail: Global casualty rates increased 2% in Q2, with U.S. excess casualty up 15% driven by elevated loss experience and a challenging litigation environment. Commercial auto accelerated 6 points QoQ. This is a positive read-through for BRO's Retail segment, which has meaningful casualty exposure and benefits from firmer pricing on renewals.
• New Business Strength Offsets Rate Headwinds — Benchmark for BRO: MMC's Marsh Risk delivered 4% underlying growth in Q2 despite property rate headwinds, driven by high single-digit new business growth in the U.S. and Canada and double-digit growth in specialties (marine, transactional risk, construction, aviation, energy). This sets a benchmark: BRO's ~0.6% organic growth consensus looks weak by comparison, and any improvement toward mid-single digits would be a positive surprise.
• E&S Market Softening — Headwind for BRO Wholesale: MMC CEO John Doyle noted "it's not a robust moment for the E&S market" as property pricing is under pressure and more business has migrated back to the admitted marketplace. This is a headwind for BRO's Wholesale Brokerage segment, which benefits from E&S market activity.
• Talent Competition Acknowledged but Not Alarming: MMC acknowledged "team raids and unethical conduct in the market" but stated colleague retention data does not support a new war for talent. This is a modest positive read-through for BRO, which has been more directly impacted by Howden-related defections.
• Overall MMC Q2 Organic: MMC delivered 5% underlying revenue growth in Q2 2026 (vs. 4% in Q1), with consolidated revenue of $7.4 billion. This acceleration is a high bar for BRO's own organic trajectory.

AJG (Arthur J. Gallagher) — Pre-Q2 2026 Investor Meeting with Management (June 17, 2026)

Relevance: AJG is BRO's closest structural peer — both are mid-to-large cap U.S.-focused insurance brokers with significant retail and specialty operations. AJG's pre-Q2 investor meeting provided explicit Q2 and full-year 2026 organic growth guidance, offering a direct benchmark.

• AJG Guiding ~5% Brokerage Organic for Q2 — Sets a High Bar vs. BRO's ~0.6%: AJG guided Q2 brokerage segment organic growth of approximately 5% and full-year 2026 of approximately 5.5%, with the gap to BRO's ~0.6% consensus almost entirely explained by Accession integration headwinds, Howden defections, and the pharmacy revenue model change. AJG's ability to deliver mid-single-digit organic in the same pricing environment underscores that BRO's weakness is company-specific, not macro.
• Property Rates Down 9–11% in Q2 — Confirms BRO's CAT Headwind: AJG reported property renewal premium changes down 9% overall for the first two months of Q2, with U.S. retail property down 11%. AJG noted large property risks are driving most of the downward pressure. Importantly, AJG does not expect another 10% sequential decline in 2027, suggesting the worst of the property rate cycle may be near. This is relevant for BRO's contingent commission outlook for 2027.
• Casualty Remains Firm — Up 5–7% in Q2: AJG reported casualty lines up 5% overall for Q2, with U.S. retail casualty up 7% (general liability +4%, commercial auto +8%, umbrella +8%). Commercial auto accelerated 6 points QoQ. This is a consistent positive read-through for BRO's Retail casualty book.
• Underlying Business Activity Remains Solid: AJG's daily revenue indications from audits, endorsements, and cancellations were still in positive territory through mid-June, pointing to solid underlying business activity. Job openings still exceed job seekers. These macro indicators support BRO's end markets.
• Customers Opting to Buy More Insurance: AJG noted across all of its business that "customers are opting in to buy more insurance" — a positive demand signal for the entire brokerage sector, including BRO.
• AI as a Margin and Revenue Driver — Validates BRO's Strategy: AJG provided detailed AI cost savings estimates: ~5% in producer/field sales costs, 10–15% in service layer, and 20–30% in back office over the next few years. This validates BRO's own AI investment thesis presented at its April 2026 investor presentation, and suggests the sector is broadly moving toward AI-driven operating leverage.
• M&A Pipeline Robust: AJG completed 15 mergers YTD representing ~$115M of annualized revenue, with a pipeline of ~40 term sheets representing ~$600M of annualized revenue. This signals continued M&A activity in the sector, which could create both acquisition opportunities and competitive dynamics for BRO.

AON — Q1 2026 Earnings Call (May 1, 2026)

Relevance: AON's Q1 2026 earnings call (reported May 1, 2026, after BRO's Q1 print) provided forward-looking commentary on Q2 2026 market conditions and reinsurance pricing, which is directly relevant to BRO's Specialty Distribution segment.

• Reinsurance Rates Down 15–20% at April 1 Renewals — Headwind for BRO Specialty: AON flagged further rate pressure at April 1 reinsurance renewals, with rates down 15–20% in both the U.S. and Japan, partially offset by approximately 10% higher demand. This is a direct headwind for BRO's Specialty Distribution segment, which has meaningful reinsurance-related revenue. However, AON still expects full-year reinsurance organic growth to meet its mid-single-digit or greater objective, supported by a strong second half.
• Commercial Risk Organic at 7% in Q1 — New Business Driving Outperformance: AON's Commercial Risk segment delivered 7% organic growth in Q1 2026 (fourth consecutive quarter at 6%+), with new business contributing over 12 points to growth. North America grew double-digit. This reinforces the theme that strong new business generation can more than offset rate headwinds — a dynamic BRO needs to demonstrate in Q2.
• Data Center Pipeline 3x Higher YoY — Specialty Growth Opportunity: AON's data center revenue pipeline is on pace to be 3x higher than last year, driven by AI, cloud computing, and digital infrastructure demand. This is a positive read-through for BRO's specialty and wholesale segments, which have exposure to complex commercial risks including data centers.
• Net Market Impact (Rate + Exposure) Still Positive at ~1 Point: Despite property rate pressure, AON's net market contribution to organic growth remained positive at approximately 1 point in Q1, and AON expects this to continue at roughly 1 point or slightly higher throughout 2026 including Q2. This suggests the rate headwind is manageable when offset by exposure growth.
• AON Reaffirms Full-Year Guidance: AON reaffirmed its 2026 guidance for mid-single-digit or greater organic revenue growth, 70–80 bps of margin expansion, and double-digit free cash flow growth. This confident tone from a large-cap peer provides a constructive backdrop for the sector heading into BRO's Q2 print.
• Talent: Revenue-Generating Population to Grow 4–8% in 2026: AON expects to expand its revenue-generating population by 4–8% in 2026 despite competitive pressures. This is a contrast to BRO's situation, where Howden-related defections have been a headwind, and suggests BRO's talent losses are company-specific rather than sector-wide.

Peer Read-Through Summary Table

7. Material News & Developments

Key Takeaway: The most important development since Q1 earnings is the Morgan Stanley downgrade to Underweight on July 6 — the first Underweight from a major bank — which signals growing sell-side concern about BRO's organic growth trajectory and valuation relative to peers, and could weigh on sentiment into the print.

• July 6, 2026 — Morgan Stanley Downgrades BRO to Underweight, PT $55: Morgan Stanley downgraded BRO from Equalweight to Underweight and cut its price target from $60 to $55, implying approximately 9.0x 2027 EV/EBITDA — a ~1 turn discount to the peer average of ~10.1x. This is the most bearish call from a major bank and reflects concern about BRO's organic growth underperformance vs. peers.
• Implication: Adds downside risk to sentiment; the Underweight rating from a major bank is a meaningful signal heading into Q2 earnings.
• July 8, 2026 — KBW Raises PT to $74, Maintains Market Perform: Keefe, Bruyette & Woods boosted its price objective on BRO from $72 to $74 while maintaining a Market Perform rating.
• Implication: Modest positive; KBW sees some value recovery but is not yet constructive enough to upgrade.
• June 26, 2026 — Raymond James Reaffirms Outperform: Raymond James reaffirmed its Outperform rating on BRO, providing a counterweight to the Morgan Stanley downgrade.
• Implication: Suggests the bull case remains intact for some analysts; stock at ~$61 at the time represented meaningful upside to their target.
• June 23, 2026 — Weiss Ratings Downgrades to Sell: Weiss Ratings lowered BRO from Hold (C-) to Sell (D+).
• Implication: Quantitative/ratings-based downgrade; less influential than sell-side research but adds to negative sentiment.
• April 29, 2026 — Truist Cuts PT to $90, Maintains Buy: Truist Financial decreased its price target from $100 to $90 and maintained a Buy rating following Q1 results.
• Implication: Bulls are trimming targets but not abandoning the thesis; $90 PT implies significant upside from current levels.
• April 14, 2026 — Bank of America Cuts PT to $88, Maintains Neutral: Bank of America decreased its price objective from $90 to $88 and maintained a Neutral rating, citing slower expected organic growth.
• Implication: BofA's Neutral reflects the consensus view — not broken, but not a compelling buy until organic growth inflects.
• May 7, 2026 — Shareholders Approve 6.9M Share Boost to Incentive Plan: BRO shareholders approved an increase of 6.9 million shares to the company's equity incentive plan at the annual meeting.
• Implication: Modest dilution signal; consistent with BRO's performance-based culture and long-term equity compensation model. Not a near-term earnings catalyst.
• July 1, 2026 — Q2 2026 Earnings Date Confirmed: BRO confirmed Q2 2026 earnings release for July 27, 2026 after market close, with conference call on July 28, 2026 at 8:00 AM EDT.
• Implication: No surprise on timing; investors have had ample time to position.
• Ongoing — Howden Talent Poaching: Annualized revenue impact from Howden-related defections grew to a higher level in Q1 2026 (though actual Q1 revenue impact was modest). Management acknowledged the situation on the Q1 call but expressed confidence in the company's values and culture.
• Implication: Watch for any update on the annualized revenue impact figure in Q2 commentary; any acceleration would be a negative catalyst.
• Ongoing — Pharmacy Consulting Revenue Model Transition: A pharmacy consulting business is transitioning from volume-based to per-employee-per-month revenue, creating a headwind of approximately 50–100 bps to retail organic growth over the next several quarters. This was first disclosed on the Q1 2026 call.
• Implication: A new, quantifiable headwind that will weigh on retail organic growth through at least Q3 2026; watch for any update on the magnitude or duration.

Analyst Rating Summary (Since Q1 2026 Earnings)

Current consensus: Hold (5 Buy / 12 Hold / 2 Sell, 19 analysts). Consensus price target: ~$78.44. Current price: ~$67.68 (July 24, 2026).

8. Insider Transaction Activity

Key Takeaway: Two directors made open-market purchases since Q1 earnings — both small in size but directionally positive; no open-market sales were filed, which is a mild constructive signal heading into Q2 earnings.

Both transactions are open-market purchases by independent directors (Form 4, transaction code P), with no 10b5-1 plan involvement, making them discretionary signals. Both purchases were made when the stock was trading near its post-Q1 lows ($54–$60 range), suggesting directors viewed the selloff as an overreaction. No open-market sales were filed by any insider during the period. The purchases are small in absolute dollar terms but are directionally constructive — insiders are buying, not selling, into weakness.

Source: SEC Form 4 filings. Window covers April 27, 2026 through July 26, 2026 (since Q1 2026 earnings). Only open-market buys (code P) and sells (code S) included; grants, awards, and option exercises excluded.